<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[ImmunAbs 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=41196></link><description><![CDATA[ImmunAbs 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Sat, 18 Apr 2026 15:08:02 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><image><url><![CDATA[https://file.newswire.co.kr/data/upfile/company_img/2022/08/12_31017998_20220804171702_2481848960.jpg]]></url></image><language>ko-KR</language><item><title><![CDATA[ImmunAbs Inc. Announces US FDA Approval for a Phase 1 Clinical Trial]]></title><link>https://www.newswire.co.kr/newsRead.php?no=949127</link><description><![CDATA[SEOUL, South Korea--(Business Wire/Korea Newswire)--ImmunAbs Inc.  announced that it has received US FDA approval for a Phase 1 clinical trial and that it is now ready to initiate a phase 1 clinical trial in the United States.  ImmunAbs is developing IM-101, a monoclonal antibody targeting complements that play essential roles in the immune system but, when out of regulation, cause various autoim...]]></description><pubDate>Thu, 04 Aug 2022 17:25:00 +0900</pubDate></item></channel></rss>